[Hinews] SEOUL, South Korea — A study led by Professor Sang-Hee Kang of the Department of Colorectal Surgery at Korea University Guro Hospital reveals that age plays a significant role in the efficacy of adjuvant chemotherapy for colorectal cancer, with age 70 identified as a key threshold.

The research team analyzed data from 8,561 patients who underwent surgery for stage II or III colorectal cancer between 2014 and 2016, all of whom received adjuvant chemotherapy. he study focused on oxaliplatin, which is a standard component of adjuvant therapy for stage III patients and is sometimes administered to high-risk stage II cases.

From left: Professors Sang Hee Kang and Jun Woo Bong, Department of Colorectal Surgery, Korea University Guro Hospital; Professors Seok Song Jung and Hwa Min Lee, Department of Biomedical Informatics, Korea University College of Medicine (Courtesy of Korea University Guro Hospital)
From left: Professors Sang Hee Kang and Jun Woo Bong, Department of Colorectal Surgery, Korea University Guro Hospital; Professors Seok Song Jung and Hwa Min Lee, Department of Biomedical Informatics, Korea University College of Medicine (Courtesy of Korea University Guro Hospital)

Among stage III patients aged 70 or younger, those treated with oxaliplatin achieved a five-year survival rate of 84.8%, compared to 78.1% for those who did not receive the drug. In contrast, patients over 70 derived minimal survival benefit and had higher rates of treatment discontinuation, most likely due to oxaliplatin’s neurotoxic side effects.

For stage II patients, oxaliplatin offered no significant survival advantage, regardless of age.

“This study clearly shows that chemotherapy outcomes can differ by age,” Professor Kang stated. “For older patients, treatment should prioritize functional status and comorbidities over simplistic age-based guidelines.”

Supported by the ICT Innovation Talent 4.0 project and Korea’s ARPA-H initiative, the study was published in JAMA Network Open under the title 'Older Age Threshold for Oxaliplatin Benefit in Stage II to III Colorectal Cancer’.

키워드

#대장암#항암치료#대장암수술#대장암치료
저작권자 © Hinews 무단전재 및 재배포 금지
ad